Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The Company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.
Website: intracellulartherapies.com



Growth: Good revenue growth rate 50.8%, there is slowdown compared to average historical growth rates 106.7%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -17.1%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 201.1% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.3x by EV / Sales multiple , the company can be 70.1% overvalued

Key Financials (Download financials)

Ticker: ITCI
Share price, USD:  (0.0%)131.87
year average price 118.18  


year start price 71.19 2024-10-07

min close price 71.19 2024-10-07

max close price 131.92 2025-03-31

current price 131.87 2025-10-07
Common stocks: 94 324 300

Dividend Yield:  0.0%
EV / Sales: 17.9x
Margin (EBITDA LTM / Revenue): -17.1%
Fundamental value created in LTM:
Market Cap ($m): 12 439
Net Debt ($m): -290
EV (Enterprise Value): 12 149
Price to Book: 10.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-24businesswire.com

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

2025-02-24zacks.com

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

2025-02-21zacks.com

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

2025-02-21globenewswire.com

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

2025-01-14zacks.com

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

2025-01-14zacks.com

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

2025-01-13businesswire.com

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

2025-01-13zacks.com

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

2025-01-13investopedia.com

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

2025-01-13zacks.com

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-07 2024-05-07 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-03-01 2022-11-03
acceptedDate 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 175M 161M 145M 132M 126M 110M 95M 87M 72M
costOfRevenue 15M 11M 10M 11M 9M 7M 7M 7M 6M
grossProfit 160M 150M 135M 121M 117M 103M 88M 81M 66M
grossProfitRatio 0.913 0.93 0.932 0.919 0.927 0.935 0.929 0.922 0.919
researchAndDevelopmentExpenses 67M 56M 43M 51M 42M 50M 38M 34M 33M
generalAndAdministrativeExpenses 0 0 0 13M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 92M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 132M 122M 113M 105M 105M 101M 99M 95M 88M
otherExpenses -216 000 -56M 0 2M 0 0 -575 000 -436 000 0
operatingExpenses 199M 178M 156M 155M 146M 150M 136M 128M 122M
costAndExpenses 214M 189M 166M 166M 156M 157M 143M 135M 127M
interestIncome 13M 12M 6M 6M 5M 5M 4M 3M 2M
interestExpense 0 0 0 4M 0 0 -4M 3M 2M
depreciationAndAmortization 138 000 129 000 132 000 136 000 135 000 123 000 134 000 143 000 170 000
ebitda -39M -28M -21M -34M -30M -47M -48M -47M -55M
ebitdaratio -0.222 -0.171 -0.144 -0.258 -0.235 -0.428 -0.511 -0.542 -0.772
operatingIncome -39M -28M -21M -34M -30M -47M -48M -47M -56M
operatingIncomeRatio -0.222 -0.172 -0.145 -0.259 -0.236 -0.428 -0.511 -0.542 -0.774
totalOtherIncomeExpensesNet 13M 12M 6M 6M 5M 5M 4M 3M 2M
incomeBeforeTax -26M -16M -15M -28M -24M -43M -44M -44M -54M
incomeBeforeTaxRatio -0.148 -0.1 -0.103 -0.214 -0.192 -0.387 -0.465 -0.504 -0.744
incomeTaxExpense 374 000 57 000 359 000 448 000 43 000 135 000 10000 -7M 1000
netIncome -26M -16M -15M -29M -24M -43M -44M -37M -54M
netIncomeRatio -0.15 -0.101 -0.105 -0.217 -0.193 -0.388 -0.465 -0.426 -0.745
eps -0.25 -0.16 -0.16 -0.3 -0.25 -0.45 -0.46 -0.39 -0.57
epsdiluted -0.25 -0.16 -0.16 -0.3 -0.25 -0.45 -0.46 -0.39 -0.57
weightedAverageShsOut 106M 104M 97M 96M 96M 96M 95M 95M 95M
weightedAverageShsOutDil 106M 104M 97M 96M 96M 96M 95M 95M 95M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-07 2024-05-07 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-03-01 2022-11-03
acceptedDate 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 464M 695M 142M 148M 99M 142M 76M 149M 135M
shortTermInvestments 542M 330M 336M 350M 394M 371M 463M 443M 493M
cashAndShortTermInvestments 1 007M 1 025M 477M 498M 493M 513M 539M 592M 629M
netReceivables 146M 146M 131M 114M 103M 96M 82M 75M 62M
inventory 24M 20M 16M 12M 43M 42M 28M 24M 24M
otherCurrentAssets 96M 76M 66M 42M 62M 46M 56M 45M 46M
totalCurrentAssets 1 272M 1 264M 691M 668M 702M 698M 706M 738M 760M
propertyPlantEquipmentNet 16M 16M 14M 15M 15M 15M 16M 17M 22M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 37M 40M 43M 46M 86 000 86 000 86 000 86 000 86 000
totalNonCurrentAssets 53M 56M 57M 60M 15M 16M 16M 17M 22M
otherAssets 0 1 1 0 0 0 0 0 0
totalAssets 1 324M 1 321M 747M 728M 718M 714M 722M 755M 782M
accountPayables 10M 18M 12M 11M 11M 8M 8M 10M 14M
shortTermDebt 8M 8M 4M 4M 4M 4M 4M 5M 7M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 147M 136M 120M 108M 89M 81M 68M 68M 56M
totalCurrentLiabilities 166M 162M 135M 124M 103M 92M 80M 83M 77M
longTermDebt 14M 14M 13M 13M 14M 14M 15M 15M 19M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 -2M
totalNonCurrentLiabilities 14M 14M 13M 13M 14M 14M 15M 15M 19M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 18M 18M 13M 17M 17M 18M 18M 20M 26M
totalLiabilities 180M 176M 148M 137M 117M 107M 95M 99M 97M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 11 000 11 000 10000 10000 10000 10000 10000 9000 9000
retainedEarnings -1 675M -1 649M -1 632M -1 617M -1 589M -1 564M -1 522M -1 477M -1 433M
accumulatedOtherComprehensiveIncomeLoss 2M -668 000 -430 000 104 000 -1M -2M -3M -4M -5M
othertotalStockholdersEquity 2 818M 2 794M 2 232M 2 208M 2 191M 2 174M 2 152M 2 138M 2 124M
totalStockholdersEquity 1 145M 1 145M 599M 591M 601M 607M 628M 656M 685M
totalEquity 1 145M 1 145M 599M 591M 601M 607M 628M 656M 685M
totalLiabilitiesAndStockholdersEquity 1 324M 1 321M 747M 728M 718M 714M 722M 755M 782M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 324M 1 321M 747M 728M 718M 714M 722M 755M 782M
totalInvestments 542M 330M 336M 350M 394M 371M 463M 443M 493M
totalDebt 18M 18M 16M 17M 17M 18M 18M 20M 26M
netDebt -447M -677M -125M -131M -82M -124M -57M -129M -109M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-07 2024-05-07 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-03-01 2022-11-03
acceptedDate 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -26M -16M -15M -29M -24M -43M -44M -44M -54M
depreciationAndAmortization 138 000 129 000 132 000 136 000 135 000 123 000 134 000 143 000 170 000
deferredIncomeTax 0 0 0 -3M -2M -2M 0 0 -1000
stockBasedCompensation 17M 16M 14M 15M 14M 13M 10M 11M 12M
changeInWorkingCapital -16M 2M -31M 14M -13M -5M -25M -8M -12M
accountsReceivables 106 000 -15M -17M -11M -7M -14M -6M -14M -15M
inventory -1M -2M -499 000 -7M -1M -14M -4M -323 000 1M
accountsPayables -7M 6M 80 000 839 000 3M -708 000 -2M -4M 3M
otherWorkingCapital -8M 13M -13M 32M -8M 23M 13M 10M -2M
otherNonCashItems -2M 25M 29M 23 000 24 000 23 000 -2M 1M 253 000
netCashProvidedByOperatingActivities -27M 542 000 -34M -2M -25M -37M -60M -39M -53M
investmentsInPropertyPlantAndEquipment -696 000 -53 000 0 -1000 -268 000 0 0 28 000 -117 000
acquisitionsNet 0 0 0 -20M 20M 0 0 0 0
purchasesOfInvestments -313M -89M -81M -104M -136M -66M -108M -116M -91M
salesMaturitiesOfInvestments 104M 96M 97M 152M 116M 161M 92M 166M 197M
otherInvestingActivites 0 8M 16M 47M -20M 0 0 0 0
netCashUsedForInvestingActivites -209M 8M 16M 47M -20M 95M -16M 50M 106M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -12M 545M 10M 3M 3M 0 4M -7000 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 7M 545M 10M 3M 3M 0 0 2M 6M
netCashUsedProvidedByFinancingActivities 7M 545M 10M 3M 3M 9M 4M 2M 6M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -229M 553M -8M 48M -43M 67M -73M 13M 58M
cashAtEndOfPeriod 466M 695M 142M 150M 101M 144M 77M 150M 137M
cashAtBeginningOfPeriod 695M 142M 150M 101M 144M 77M 150M 137M 79M
operatingCashFlow -27M 542 000 -34M -2M -25M -37M -60M -39M -53M
capitalExpenditure -696 000 -53 000 0 -1000 -268 000 0 0 28 000 -117 000
freeCashFlow -27M 489 000 -34M -2M -26M -37M -60M -39M -53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-30 11:30 ET
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
2024-10-17 12:00 ET
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
2024-09-23 12:00 ET
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
2024-08-28 12:00 ET
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
2024-08-08 12:00 ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
2024-08-07 11:40 ET
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
2024-08-07 11:30 ET
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
2024-07-24 12:00 ET
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
2024-06-18 11:30 ET
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
2024-06-10 12:00 ET
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
2024-05-29 12:00 ET
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
2024-05-23 12:00 ET
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
2024-05-08 12:00 ET
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
2024-05-07 11:30 ET
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
2024-04-30 12:00 ET
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
2024-04-24 20:01 ET
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-04-24 20:01 ET
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-04-18 00:46 ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
2024-04-16 20:06 ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
2024-04-16 11:00 ET
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
2024-03-19 12:30 ET
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
2024-03-06 13:00 ET
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
2024-02-27 13:00 ET
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
2024-02-22 12:30 ET
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
2024-02-08 13:00 ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
2024-01-02 13:00 ET
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 13:00 ET
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
2023-11-15 13:00 ET
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-02 11:30 ET
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
2023-10-31 12:00 ET
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
2023-10-26 12:00 ET
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
2023-09-20 12:00 ET
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
2023-09-11 12:00 ET
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
2023-09-05 12:00 ET
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-04 12:00 ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-08-03 11:30 ET
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
2023-07-28 12:00 ET
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
2023-06-05 12:00 ET
Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-31 12:00 ET
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
2023-05-04 11:30 ET
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-02 12:00 ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
2023-04-26 12:00 ET
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
2023-04-11 12:00 ET
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
2023-03-28 11:00 ET
Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
2023-03-01 12:30 ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
2023-02-14 13:00 ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
2023-02-08 13:00 ET
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
2023-01-03 13:00 ET
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 13:00 ET
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
2022-11-10 13:00 ET
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
2022-11-03 11:30 ET
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-27 12:00 ET
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
2022-08-09 11:30 ET
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-08-02 12:00 ET
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
2022-06-13 12:00 ET
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
2022-05-10 11:30 ET
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-03 12:00 ET
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
2022-04-25 11:00 ET
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
2022-04-21 12:00 ET
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
2022-04-05 12:00 ET
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
2022-03-01 12:30 ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
2022-02-22 13:00 ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
2022-02-10 13:00 ET
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-07 21:01 ET
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2022-01-05 03:05 ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
2022-01-03 21:01 ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
2022-01-03 13:00 ET
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-20 11:47 ET
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
2021-12-06 21:01 ET
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
2021-11-09 12:30 ET
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-02 12:00 ET
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
2021-10-18 12:00 ET
Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20
2021-10-08 12:00 ET
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
2021-09-27 11:30 ET
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
2021-09-22 12:00 ET
Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
2021-09-20 11:30 ET
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
2021-08-10 12:00 ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
2021-08-09 11:30 ET
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-02 12:00 ET
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast
2021-06-07 12:00 ET
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
2021-05-26 12:00 ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
2021-05-10 11:30 ET
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-05 12:00 ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
2021-05-04 12:00 ET
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
2021-05-03 11:30 ET
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
2021-04-22 11:30 ET
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
2021-04-20 11:00 ET
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
2021-04-12 11:30 ET
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
2021-02-25 12:30 ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
2021-02-24 12:30 ET
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
2021-02-22 13:00 ET
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
2021-02-19 13:00 ET
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-17 13:00 ET
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
2021-01-21 13:00 ET
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
2021-01-05 13:00 ET
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-29 13:00 ET
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
2020-12-09 13:00 ET
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
2020-11-30 13:00 ET
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
2020-11-09 12:30 ET
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-11-04 13:00 ET
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
2020-10-02 11:00 ET
New Ventures Funds Rebrands as Scientia Ventures
2020-10-01 20:30 ET
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
2020-09-15 12:00 ET
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-14 12:00 ET
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
2020-09-11 00:30 ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
2020-09-09 20:01 ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
2020-09-09 11:00 ET
Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
2020-08-10 11:30 ET
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-08-04 12:00 ET
Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
2020-06-29 12:00 ET
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
2020-05-14 12:00 ET
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
2020-05-13 20:15 ET
Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
2020-05-07 11:30 ET
Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-04-29 12:00 ET
Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast
2020-04-16 20:45 ET
Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-04-02 12:00 ET
Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
2020-03-23 11:30 ET
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
2020-03-02 12:30 ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
2020-02-24 13:00 ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast
2020-02-21 21:15 ET
Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-02-20 22:00 ET
Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry
2020-02-18 13:00 ET
Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-01-08 02:47 ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
2020-01-06 21:06 ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
2020-01-02 13:00 ET
Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-23 11:59 ET
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
2019-12-12 12:30 ET
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology
2019-12-04 13:00 ET
Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
2019-11-05 12:30 ET
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
2019-10-29 12:00 ET
Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
2019-09-30 12:00 ET
Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference
2019-09-25 11:30 ET
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
2019-09-10 11:30 ET
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
2019-04-15 11:00 ET
Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
2019-04-09 12:00 ET
Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the Schizophrenia International Research Society
2019-03-26 11:00 ET
Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs

SEC forms

Show financial reports only

SEC form 10
2025-02-21 09:00 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 8
2025-02-21 08:21 ET
Intra-Cellular Therapies reported for 2024 q4
SEC form 8
2025-02-21 08:21 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 10
2024-10-30 07:53 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 8
2024-10-30 07:44 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 8
2024-10-30 07:44 ET
Intra-Cellular Therapies published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 10
2024-08-07 07:55 ET
Intra-Cellular Therapies reported for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies reported for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 10
2024-05-07 07:43 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-05-07 07:40 ET
Intra-Cellular Therapies reported for 2024 q1
SEC form 8
2024-05-07 07:40 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 10
2024-02-22 07:42 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2024-02-22 07:39 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2024-02-22 07:39 ET
Intra-Cellular Therapies reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2023-11-02 08:01 ET
Intra-Cellular Therapies published news for 2023 q3
SEC form 10
2023-11-02 08:01 ET
Intra-Cellular Therapies reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Intra-Cellular Therapies published news for 2023 q3
SEC form 10
2023-08-03 07:44 ET
Intra-Cellular Therapies reported for 2023 q2
SEC form 6
2023-08-03 07:39 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 6
2023-06-23 16:15 ET
Intra-Cellular Therapies published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Intra-Cellular Therapies published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Intra-Cellular Therapies reported for 2023 q1
SEC form 6
2023-03-28 07:12 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 10
2023-03-01 07:46 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 6
2023-03-01 07:41 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 6
2023-01-09 17:13 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 6
2022-12-22 16:09 ET
Intra-Cellular Therapies published news for 2022 q3
SEC form 10
2022-11-03 07:46 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 6
2022-11-03 07:35 ET
Intra-Cellular Therapies published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 10
2022-08-09 07:47 ET
Intra-Cellular Therapies reported for 2022 q2
SEC form 6
2022-08-09 07:38 ET
Intra-Cellular Therapies published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Intra-Cellular Therapies published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Intra-Cellular Therapies reported for 2022 q2
SEC form 6
2022-06-13 17:01 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 10
2022-05-10 07:46 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 6
2022-05-10 07:37 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 6
2022-04-25 07:12 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 17:01 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 16:52 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 08:08 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-03-01 07:49 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 10
2022-03-01 07:46 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-07 16:12 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-05 17:06 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-05 16:58 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 8
2022-01-04 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-03 17:38 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2021-12-29 16:11 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-12-20 07:04 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-12-08 16:33 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 10
2021-11-09 07:53 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-11-09 07:49 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-08-09 07:37 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 10
2021-08-09 07:31 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 6
2021-06-22 16:30 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-06-22 16:09 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-05-10 07:37 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 10
2021-05-10 07:31 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-05-03 07:42 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-04-29 17:05 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-04-19 17:28 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-02-25 07:54 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 10
2021-02-25 07:46 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 6
2021-02-22 08:09 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 10
2020-11-09 07:45 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-11-09 07:40 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-10-28 16:02 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-10-01 16:38 ET
Intra-Cellular Therapies published news for 2020 q3